Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Deals

Shanghai BioScience Completes RMB 100M Financing Round Led by HUAGAI Capital

Fineline Cube Mar 4, 2025

China-based Shanghai BioScience Co., Ltd., a life sciences service platform, announced the completion of a...

Company Deals Digital

Bayer HealthCare and JD Healthcare Partner on Women’s Health Ecosystem

Fineline Cube Mar 4, 2025

German pharmaceutical giant Bayer HealthCare (ETR: BAYN) has entered into a new partnership with JD...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Medical Device

Bio-heart’s Iberis RDN System Completes First Commercial Surgery in Germany

Fineline Cube Mar 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced the successful completion of its...

Company Deals

Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions

Fineline Cube Mar 4, 2025

Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has...

Company Drug

Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt

Fineline Cube Mar 4, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...

Company Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

Fineline Cube Mar 4, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...

Company Drug

CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors

Fineline Cube Mar 4, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...

Company Deals

AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal

Fineline Cube Mar 3, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...

Company Medical Device

Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA

Fineline Cube Mar 3, 2025

Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...

Company Drug

Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials

Fineline Cube Mar 3, 2025

Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...

Company Drug

SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

Fineline Cube Mar 3, 2025

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...

Company Deals

Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone

Fineline Cube Mar 3, 2025

A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a...

Company Deals

WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects

Fineline Cube Mar 3, 2025

WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has...

Company Drug

Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda

Fineline Cube Mar 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...

Deals Drug

Eyebright Medtech Plans Private Placement to Expand Contact Lens Production

Fineline Cube Mar 3, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...

Company Drug

Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment

Fineline Cube Mar 3, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...

Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Posts pagination

1 … 226 227 228 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.